Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Len Neckers

Showing results (151-160 of 168) with videos related to

Pageof 17
Sort By:
Chemistry & Biology|September 17, 2013
Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cellsJared J Barrott, Philip F Hughes, Takuya Osada, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 20, 2015
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric LigandsSara Sattin, Jiahui Tao, Gerolamo Vettoretti, et al.
Cell Cycle (Georgetown, Tex.)|September 1, 2012
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cellsAki Iwai, Dimitra Bourboulia, Mehdi Mollapour, et al.
Cancer Genetics and Cytogenetics|December 8, 2009
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancerYoufeng Yang, Vladimir A Valera, Hesed M Padilla-Nash, et al.
Hepatology (Baltimore, Md.)|June 11, 2015
Alternative splicing of the cell fate determinant Numb in hepatocellular carcinomaYinying Lu, Wanping Xu, Junfang Ji, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Oncotarget|March 15, 2018
Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancersCarole Sourbier, Pei-Jyun Liao, Christopher J Ricketts, et al.
Molecular Cell|February 18, 2010
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone functionMehdi Mollapour, Shinji Tsutsumi, Alison C Donnelly, et al.
Cancer Cell|December 10, 2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancerCarole Sourbier, Christopher J Ricketts, Shingo Matsumoto, et al.
Pageof 17

Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Chemistry & Biology|September 17, 2013
Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cellsJared J Barrott, Philip F Hughes, Takuya Osada, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 20, 2015
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric LigandsSara Sattin, Jiahui Tao, Gerolamo Vettoretti, et al.
Cell Cycle (Georgetown, Tex.)|September 1, 2012
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cellsAki Iwai, Dimitra Bourboulia, Mehdi Mollapour, et al.
Cancer Genetics and Cytogenetics|December 8, 2009
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancerYoufeng Yang, Vladimir A Valera, Hesed M Padilla-Nash, et al.
Hepatology (Baltimore, Md.)|June 11, 2015
Alternative splicing of the cell fate determinant Numb in hepatocellular carcinomaYinying Lu, Wanping Xu, Junfang Ji, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Oncotarget|March 15, 2018
Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancersCarole Sourbier, Pei-Jyun Liao, Christopher J Ricketts, et al.
Molecular Cell|February 18, 2010
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone functionMehdi Mollapour, Shinji Tsutsumi, Alison C Donnelly, et al.
Cancer Cell|December 10, 2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancerCarole Sourbier, Christopher J Ricketts, Shingo Matsumoto, et al.
Pageof 17